Alpha Fusion Inc.
PrivateLast Round
Series B
Oct 9, 2024
Total Funding Raised
$10.04M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alpha Fusion Inc. operates in Healthcare & Life Sciences and is based in Osaka. Its latest recorded funding round was a Series B round in October 2024.
Alpha Fusion Inc. is a biotechnology company developing targeted alpha therapy (TAT) using astatine-211 for cancer treatment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alpha Fusion Inc. Comparables
Compare Alpha Fusion Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Atonco | 86% | |
| Z-Alpha Therapeutics | 83% | |
| Skopos Bio | 82% |
For institutional investors. Book with your work email.
Alpha Fusion Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 9, 2024 | ||||
| Series A | Mar 8, 2023 |
For institutional investors. Book with your work email.
Alpha Fusion Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kobe University Capital | Series B |
| Global Brain Corporation | Series A |
| Joyo Capital Partners | Series B |
| Japan Science and Technology Agency | Series A |
| OUVC | Series A, Series B |
| SBI Investment Co., Ltd. | Series B |
| D3 LLC | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Added Hanson Wade, an events and business intelligence company, as a customer.
- May 26, 2026
Added Targeted Radiopharma, a biotechnology startup, as a customer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 17, 2026
Alpha Fusion, Inc. agrees to appoint Dr. Alison Armour as Chief Medical Officer as it advances a planned integration of Astatine-211 programs with Curadh MTR in Japan on Sep 17th '26.
For institutional investors. Book with your work email.
Alpha Fusion Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alpha Fusion Inc.'s valuation, stock price, and market status.
Is Alpha Fusion Inc. a public or private company?
Alpha Fusion Inc. is a private company.
What is the current stock price of Alpha Fusion Inc.?
Alpha Fusion Inc. is a private company, so its shares have no public market price. Caplight tracks Alpha Fusion Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alpha Fusion Inc. worth (valuation)?
Valuation information for Alpha Fusion Inc. is not publicly available.
Can I buy Alpha Fusion Inc. stock?
Alpha Fusion Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alpha Fusion Inc.'s last funding round?
Alpha Fusion Inc.'s most recent funding round was Series B on October 9, 2024.
Who are the main investors in Alpha Fusion Inc.?
Key investors in Alpha Fusion Inc. include OUVC, SBI Investment Co., Ltd..
Will Alpha Fusion Inc. IPO soon?
No public IPO plans have been announced for Alpha Fusion Inc..
How can I track Alpha Fusion Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Alpha Fusion Inc.'s shares on secondary markets.